Atlantis Healthcare Appoints New Chairman
Neil Matheson has been appointed Non-Executive Chairman of the Board for Atlantis Healthcare, the company that leverages the latest health psychology, data, and behavioral sciences to develop and deliver personalized, cost-effective solutions to healthcare customers. Matheson’s goal is to drive global growth of the company’s personalized interventions to improve health outcomes.
“Neil comes to us with an impressive track record in founding, building, and managing successful healthcare service and communication businesses,” said Jonny Duder, CEO, Atlantis Healthcare. “Beyond his vast experience in global market strategy, Neil brings a genuine passion around patient empowerment, patient education, and maximizing patient outcomes—values closely aligned with our corporate mission.” Matheson was most recently Global CEO of Huntsworth Health and has experience spanning the healthcare spectrum.
Omnicom’s CDM Expands Executive Team
Part of Omnicom Health Group, the CDM Network has promoted Craig Romanok, previously Managing Partner, Director of Client Services, to President CDM Princeton. During his 19 years at CDM Princeton, Romanok became known as a big thinker and passionate advocate of life-changing strategic and creative work. He will continue to focus on transformative brands and on the clients who promise to change the world for the better.
“For the past two years, CDM Princeton has built an agency model on the idea of ‘Life changing,’ Romanok says. “It is my pleasure to continue that trajectory as president of one of the world’s most admired healthcare advertising agencies. During my tenure, CDM Princeton has brought the best people, brands, and innovation together to change real lives.”
AbelsonTaylor
The largest independent health and wellness advertising agency, announces growth of their shareholder group with Lynnette Hunter, Senior Vice President, Account Director, and Tristen George, Senior Vice President, Experience Design. Both are joining the agency’s Executive Committee and will participate in all important decisions pertaining to the organization’s business and policies. Hunter joined the company in 2000 as Traffic Coordinator, rising in the ranks as she established a strong reputation for leadership, accountability, and progressive business thinking. She has also played a key role in developing AbelsonTaylor’s strength in digital marketing and consumer engagement. George joined AbelsonTaylor in 2008 as a Senior Art Director and created the agency’s Experience Design Group (ExD) in 2015.
Aptose Biosciences Inc.
Jotin Marango, MD, PhD, is now SVP, Chief Business Officer of the clinical-stage developer targeting the underlying mechanisms of cancer. He is now responsible for Aptose’s corporate and business development initiatives, including licensing and alliance management, business and product strategy, as well as market and competitive intelligence. Dr. Marango most recently served as a Senior Research Analyst at ROTH Capital Partners.
Immunome
The biotech company that transforms the most educated components of the human immune system from cancer patients into novel therapeutics, announces that industry veteran Purnanand Sarma, PhD, is the new President and Chief Executive Officer. With his 25 years of experience in drug development, fund raising, and growing companies across multiple R&D platforms, Dr. Sarma is excited to join Immunome and create what could be a revolution in oncology drug discovery.
Eiger BioPharmaceuticals
The rare disease focused company appoints Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs. Dr. Mannebach has spent 30 years with leadership roles at industry greats like Pfizer and Baxter. He brings his vast experience in global regulation and development of branded and specialty pharmaceuticals and biologics to furthering Eiger’s rare and ultra-rare disease programs.
Entasis Therapeutics
David Meek was appointed as Chairman of the Board of Directors of the biopharma company focused on novel antibacterial products. Meek is currently the CEO and Board Member of Ipsen Pharmaceuticals, and serves on the Board of Directors of uniQure, PhRMA, and EFPIA. He will use his 25 years of experience to help translate Entasis’ antimicrobial pipeline of programs to a portfolio of successful, life-saving products that treat severe multi-drug resistant infections.
EyePoint Pharmaceuticals
The specialty biopharma announces Scott Jones as their new Chief Commercial Officer. He will be responsible for commercialization of Dexycu, a treatment of postoperative inflammation following cataract surgery and Yutiq, a treatment of chronic non-infectious uveitis. He was most recently CCO and VP, Business Development at Notal Vision, where he gained more than ample experience in commercializing drugs and devices globally.
F-star
Louis Kayitalire, MD, becomes Chief Medical Officer of the biopharma company delivering tetravalent bispecific antibodies for cancer therapy. Dr. Kayitalire will oversee the clinical development of F-star’s lead product candidate, FS118, a LAG-3/PD-L1-targeting tetravalent bispecific antibody, currently in Phase 1 trials. He will also lead clinical strategy and operations for the full pipeline of immuno-oncology bispecific antibody therapeutics.
Klick Health
The marketing agency added accomplished media and marketing executive Dave Leitner to its team as SVP of Media. Leitner has led companies through the customer journey to achieve measurable goals using actionable marketing strategies throughout his 25-year career. The marketing executive will now head Klick’s expansion in the rapidly growing healthcare market.
Health Monitor Network
The leading DTP/DTC patient engagement company in the U.S., adds three new accomplished executives to its management team: Paul Wituschek, Chief Commercial Officer; Joseph DiCarlo, Chief People Officer; and David Zuern, SVP, Operations. With 30 years of experience in global sales, marketing, and consulting, Wituschek will lead HMN in hyper growth in the marketplace. DiCarlo, a 20-year industry veteran, will be responsible for building and optimizing high-performance teams. Zuern possesses more than 30 years of diverse operations management experience in distribution, logistics, customer service, purchasing, and inventory management. He will produce operational improvements in safety, quality, delivery, cost, and culture.
